SMS Lifesciences shares soar 17% after U.S. FDA clears Telangana facility with no regulatory action indicated in inspection.

• API unit gets “voluntary action indicated” rating; no regulatory action expected post-inspection report from the U.S. FDA.
• Stock sees its strongest day since August 2024, moving above key 50, 100, and 200-day moving averages.
• Trading volume surges 70 times normal; SMSL now up 13.4% year-to-date after recent session gains.